JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Thursday, Stifel analysts maintained a Buy rating and a $28.00 price target on Phathom Pharmaceuticals (NASDAQ:PHAT) stock, representing significant upside potential from current levels. According to InvestingPro data, analyst consensus remains bullish with targets ranging from $17 to $28, despite the stock’s 65% decline over the past six months. The firm’s analysts highlighted the company’s effective execution of Voquezna™’s commercialization strategy. Phathom Pharmaceuticals has successfully navigated the market since gaining full access in July, achieving near-maximal insurance coverage in less than a year since the product’s launch, and engaging in an effective direct-to-consumer (DTC) advertising campaign.
Voquezna™ ended 2024 with sales surpassing expectations, generating $29.7 million, which was 81% higher quarter-over-quarter and exceeded the consensus estimate of $24.9 million. This performance underscores the strong ongoing demand for the product. InvestingPro analysis indicates the company is expected to maintain strong momentum, with revenue growth forecast at 73.9% for FY2024. Get access to detailed financial forecasts and 8 additional ProTips about PHAT’s growth prospects through InvestingPro’s comprehensive research reports. The company has also made significant progress with the full approval of NERD, securing contracts with most major insurance plans, and expanding its reach to over 20,000 prescribers, moving beyond gastroenterology specialists to primary care, where the majority of potential patients are located.
The analysts pointed out that Phathom Pharmaceuticals’ positive developments are shadowed by the current 180-day waiting period following its Citizen Petition (CP) as the company seeks to secure a legal 10-year exclusivity period for its product. The Stifel team anticipates that once this period concludes and the exclusivity is presumably granted, Phathom’s stock will reflect the company’s robust performance and growing demand for its product. While the company maintains a strong current ratio of 5.73, indicating solid short-term financial health, InvestingPro’s Fair Value analysis suggests the stock may be currently undervalued.
In other recent news, Phathom Pharmaceuticals Inc reported a significant rise in revenue for the fourth quarter of 2024. The company achieved net revenues of $29.7 million, marking an 81% increase from the previous quarter. Phathom Pharmaceuticals maintained a strong gross margin of 87% during this period and ended the year with $297 million in cash and cash equivalents. The company’s key product, Vequesna, has shown promising market penetration, contributing to the full-year revenue of $55.3 million. Phathom Pharmaceuticals is exploring an over-the-counter strategy for Vequesna and expanding its product line, with plans to focus on increasing adoption among primary care physicians. The company projects revenue of approximately $165 million for 2025. The potential for Vequesna to reach blockbuster status is highlighted by CEO Terry Curran, reflecting the company’s confidence in its flagship product. The company is also considering new indications such as Eosinophilic Esophagitis to expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.